

## ASX ANNOUNCEMENT

9 February 2016

ASX Limited  
20 Bridge Street  
SYDNEY NSW 2000

### A\$75 Million Private Placement and A\$7.5 Million Share Purchase Plan

#### Highlights

- **Commitments received under share placement to sophisticated and professional investors to raise A\$75 million at an issue price of A\$0.95 per share**
- **Proceeds to be used to expand and accelerate sales and marketing of L-Dex and pursue significant opportunity in Chronic Heart Failure**
- **Share Purchase Plan to be offered to existing eligible shareholders at same issue price as placement**

#### Placement

ImpediMed Limited (ABN 65 089 705 144) (ASX: IPD) (**ImpediMed** or the **Company**) is pleased to announce that it has received commitments from sophisticated and professional investors to subscribe for 78,947,368 new fully paid ordinary shares in the Company (**New Shares**) at an issue price of A\$0.95 per New Share, raising A\$75 million (**Placement**).

The Placement will be completed in two tranches with Tranche 1 consisting of 44,062,855 New Shares to be issued under ImpediMed's 15% placement capacity in accordance with ASX Listing Rule 7.1. Tranche 2 will consist of 34,884,513 New Shares to be issued subject to shareholder approval at a general meeting to be convened by the Company on or about 15 March 2016.

Canaccord Genuity (Australia) Limited acted as sole lead manager and bookrunner for the Placement.

The funds raised from the Placement will be primarily used by the Company to:

- expand sales and marketing activities for L-Dex®;
- allow for balance sheet flexibility and working capital expansion to drive additional L-Dex growth in both the US and international markets;
- pursue the Chronic Heart Failure (**CHF**) business, including by completing the 510(k) process and conducting and completing a clinical trial in CHF to position the Company with clinical data in support of a future product launch in CHF; and

- provide for balance sheet strength in the context of high levels of commercial and corporate inquiry being generated by the Company.

The New Shares subscribed for under Tranche 1 of the Placement are expected to be issued on Tuesday, 16 February 2016. The New Shares will rank equally with existing ImpediMed shares.

### **Share Purchase Plan**

In addition to the Placement, the Company is offering shareholders with registered addresses in Australia and New Zealand the opportunity to subscribe for up to approximately A\$15,000 in New Shares under a Share Purchase Plan (**SPP**). The issue price under the SPP is A\$0.95 per New Share, which is the same price as under the Placement. The amount to be raised under the SPP will be capped at A\$7.5 million. The proceeds of the SPP will be used by the Company for the same purposes as the Placement.

The record date for the SPP is 7pm (Sydney time), Monday, 8 February 2016. Full details of the SPP will be released to ASX and mailed to eligible shareholders shortly.

Richard Carreon, ImpediMed's CEO and Managing Director said "This is an exciting time for ImpediMed. With our US national launch of L-Dex successfully underway and our compelling opportunity in Chronic Heart Failure rapidly evolving, we are delighted to have received such strong support and endorsement for this capital raising from existing and new institutional and sophisticated shareholders. This raising provides us with significant balance sheet strength to drive our business."

-ENDS-

**Richard Carreon**  
**Managing Director & CEO**

**For further information contact:**

**Richard Carreon, ImpediMed Managing Director & CEO**  
**Morten Vigeland, ImpediMed CFO**  
**T: +1 (760) 585-2100**

**Kyahn Williamson, Buchan**  
**Investor and Media Relations**  
**T: +61 3 9866 4722**  
**E: [kwilliamson@buchanwe.com.au](mailto:kwilliamson@buchanwe.com.au)**